Pittsburgh-based Lipella Pharmaceuticals Inc. was a clinical-stage biotechnology company that developed therapies using proprietary liposomal drug delivery technology. Its candidates advanced into FDA-authorized clinical trials, including Phase 2 studies addressing oral lichen planus and hemorrhagic cystitis. Following a court-approved 2026 sale of its development programs and related intellectual property, Lipella concluded its research and development activities.
FDA Orphan Drug Designation for LP-10 (Hemorrhagic Cystitis)
Registration
FDA Orphan Drug Designation for LP-10 (Oral Graft versus Host Disease)
Registration
Generian PharmaceuticalsFormed by UPMC Enterprises, Generian Pharmaceuticals is a Boston- and Pittsburgh-based preclinical biotechnology company developing orally available small-molecule therapeutics for difficult-to-drug diseases often dominated by biologics. Its discovery platform screens proteins in their native cellular environment, then combines target-binding data with disease-relevant phenotypic testing to advance candidates that modulate protein activity, stability, or degradation. The company’s research includes proprietary programs and a collaboration with Astellas for novel targets.
Saptalis Pharmaceuticals, LLCFounded in 2015, Saptalis Pharmaceuticals is a privately held U.S. specialty pharmaceutical company known for developing prescription therapies in niche areas, particularly for patients who need more specialized dosage forms. Its Hauppauge, New York operation supports drug development and manufacturing for pediatric and geriatric care, including oral liquids and sterile ophthalmic products.HAUPPAUGE, NY
Duo OncologyFounded by nanoparticle and drug-delivery researchers, Pittsburgh-based Duo Oncology is a clinical-stage biotechnology company developing tumor-activated medicines for cancer treatment. Its lead program, DUO-207, is designed to simplify chemotherapy by concentrating drug activity in tumors while reducing exposure in healthy tissue.PITTSBURGH, PA